Despite a generally bearish sentiment, the
Zoetis (ZTS) stock remains an object of discussion among investors and analysts. While some reports suggest
weaker sales projections stirring debate ahead of Q4 2025 earnings and a price target cut to $130 due to the aggressive 2026 revenue outlook, others point to ZTS's solid profit margins, reliable dividends, favorable opinions from CVMP for Portela®, and
approval of Lenivia for canine osteoarthritis pain as a reason for potential growth. The company's shares saw a dip along with the overall market, but have demonstrated robust recovery with a 1.7% rise post-earning report. However, a recent stock plummet questions the dividend growth story. AI diagnostics, new EU product approvals, potential long-acting Anti-NGF therapy for cats, and recent
share price weakness have positioned ZTS as a potentially attractive opportunity for long-term investors. Their push towards AI infectious disease diagnostics in the wake of rising zoonotic disease concerns is a testament to their robust
innovation embarkment.
Zoetis ZTS News Analytics from Wed, 21 May 2025 07:00:00 GMT to Sat, 17 Jan 2026 13:21:21 GMT -
Rating 5
- Innovation 6
- Information 7
- Rumor -6
